All In Biotech

Drug Trial Radar · NCT04606264

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

Randomized, Embedded, Multifactorial Adaptive Platform for Perioperative Medicine at UPMC (UPMC REMAP): Core Protocol - Enhanced Recovery Protocols (ERP)

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,395

Actual

Start

May 15, 2023

Primary completion

Mar 21, 2025

Study completion Mar 21, 2025

Sponsor

Lead sponsor
Jennifer Holder-MurrayAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Berry Consultants
First posted
Oct 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This REMAP Periop ERP domain study falls under the Periop Core Protocol, which compares the different recommended strategies for enhancing recovery through the use of various standard of care treatments before, during and after surgery in all patients with elective surgical encounters at UPMC who meet eligibility criteria. The ERP domain seeks to enhance recovery by optimizing strategies of perioperative care through evaluating combinations of perioperative treatment, which consists of preoperative, intraoperative and postoperative care. Optimal combinations of perioperative care will be generated and analyzed to determine the best outcomes for patients as defined by reduction in hospital free days, reduction in postoperative nausea and vomiting, and improved pain control.

Conditions

  • Perioperative Optimization

Interventions

  • Neuraxial AnalgesiaDrug

    This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).

  • Regional Block 1: ParavertebralDrug

    This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)

  • PerphenazineDrug

    This randomized group will receive 8 mg of perphenazine orally preoperatively.

  • AprepitantDrug

    This randomized group will receive 40 mg of aprepitant orally preoperatively.

  • DimenhydrinateDrug

    This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.

  • Ondansetron 4 MGDrug

    This randomized group will receive 4 mg of ondansetron orally.

  • DexamethasoneDrug

    This randomized group will receive 4-5 mg of dexamethasone intravenously.

  • Regional Block 2: QL1Drug

    This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30 Day Hospital Free DaysTime frame: Day 0 - Day 30

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • UPMC Magee-Womens Hospital

    Pittsburgh, Pennsylvania

  • UPMC Presbyterian

    Pittsburgh, Pennsylvania

  • UPMC Passavant

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.